Authors
Latest:
Combining and Sequencing FLT3 Inhibitors in AMLHarry Erba, MD, PhD; Courtney DiNardo, MD; Mark Levis, MD, PhD; and Vinod Pullarkat, MD, review factors to consider when using combining and/or sequencing first- or second-generation FLT3 inhibitors for patients with acute myeloid leukemia (AML).
Latest:
Dr. Mann on Differences Between Treatments for Prostate CancerMark J. Mann, MD, assistant professor, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses the differences between treatment options for patients with prostate cancer subtypes.
Latest:
Dr. Roschewski on the Use of DA-EPOCH-R in Burkitt LymphomaMark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses the use of dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (Rituxan; DA-EPOCH-R) in patients with Burkitt lymphoma.
Latest:
Dr. Truty on Challenges With Treating Patients With Pancreatic CancerMark J. Truty, MD, MS, assistant professor of surgery, Mayo Clinic, discusses challenges with treating patients with pancreatic cancer.
Latest:
Dr Levis on Maintenance Gilteritinib After ASCT in FLT3-ITD+ AMLMark J. Levis, MD, PhD, discusses data from the phase 3 BMT CTN 1506/MORPHO trial of gilteritinib as maintenance therapy following allogeneic stem cell transplant in patients With FLT3-ITD–positive acute myeloid leukemia.
Latest:
Dr. Zalupski on Implications of the KEYNOTE-061 Trial in Gastric CancerMark M. Zalupski, MD, professor of medicine at the University of Michigan School of Medicine, discusses the clinical implications of the phase III KEYNOTE-061 trial in gastric cancer.
Latest:
Dr. Gilbert on Precision Medicine in GlioblastomaMark R. Gilbert, MD, senior investigator, chief, Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, discusses the use of precision medicine in treating patients with glioblastoma.
Latest:
Dr. Litzow on New Immunologic Therapies in ALLMark R. Litzow, MD, a professor of Medicine in the Division of Hematology at the Mayo Clinic in Rochester, Minnesota, discusses novel immunologic therapies for the treatment of patients with acute lymphoblastic leukemia (ALL).
Latest:
Dr. Soberman on Theme of Next-Generation Multidisciplinary Care for Patients With CancerMark S. Soberman, MD, MBA, FACS, the 2017 to 2018 President of the Association of Community Cancer Centers (ACCC), discusses his presidential theme of next-generation multidisciplinary care for patients with cancer.
Latest:
Dr. Talamonti on Advantages with Minimally Invasive Surgery for Pancreatic CancerMark S. Talamonti, MD, clinical professor, NorthShore University HealthSystem, discusses the advantages of minimally invasive surgery for patients with pancreatic cancer.
Latest:
Dr. Scholz on Significance of ARAMIS Trial in CRPCMark Scholz, MD, medical director, Prostate Oncology Specialists, discusses the significance of the ARAMIS trial in the treatment of patients with metastatic castration-resistant prostate cancer.
Latest:
Dr. Schroeder on Tolerability of Treatment For MyelomaMark Schroeder, MD, assistant professor of medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the tolerability of treatment regimens for patients with relapsed/refractory myeloma.
Latest:
Dr. Shapiro Discusses Bosutinib in CMLMark Shapiro, MD, PhD, discusses bosutinib as treatment for patients with CML.
Latest:
Dr. Sisco Discusses Complications After Bilateral and Unilateral Mastectomies with Immediate ReconstructionMark Sisco, MD, Clinical Assistant Professor, Division of Plastic and Reconstructive Surgery, NorthShore Univeristy HealthSystem, discusses the results of a NSQIP analysis of 30-day complications after bilateral versus unilateral mastectomy with immediate reconstruction
Latest:
Dr. Stein on AR-Resistance in Prostate CancerMark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses androgen receptor–resistance in prostate cancer.
Latest:
Dr. Fleming on the Rationale of the SPOTLIGHT Trial in Prostate CancerMark T. Fleming, MD, discusses the rationale and results from the phase 3 SPOTLIGHT trial in prostate cancer.
